Thoracic Radiotherapy Does Not Prolong Survival in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer
- 1 July 1990
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 113 (1) , 33-38
- https://doi.org/10.7326/0003-4819-113-1-33
Abstract
Study Objective: To compare the survival of patients with locally advanced non-small cell lung cancer treated with single-agent vindesine, thoracic radiotherapy, or both treatment modalities. Design: Randomized, prospective, phase III trial. Setting: Multi-institutional, university-based national cooperative oncology group. Patients: The study included 319 patients with locally advanced, unresectable non-small cell lung cancer who had no evidence of extrathoracic metastases. All patients were ambulatory and had measurable disease. Some patients could not have surgery because of coexisting medical conditions. Intervention: Patients were randomly assigned to receive vindesine, 3 mg/m2 body surface area weekly; standard thoracic radiotherapy, 60 Gy over 6 weeks; or both vindesine and thoracic radiotherapy. Vindesine was administered for 6 weeks and then every other week to patients who had no disease progression. Patients who developed progressive disease while receiving vindesine or radiotherapy alone were crossed over to radiotherapy or vindesine, respectively. Response assessment took place at week 6. Results: The overall response rate was superior in the radiotherapy arms (radiotherapy alone, 30%; radiotherapy plus vindesine, 34%; vindesine alone, 10%; P = 0.001). However, with a minimum follow-up of 42 months, no improvement in survival has been seen with radiotherapy. The median survival was 8.6 months for patients receiving radiotherapy alone, 9.4 months for those receiving radiotherapy plus vindesine, and 10.1 months for those receiving vindesine (P = 0.58). Radiotherapy also failed to improve long-term survival. The 5-year survivals were 3%, 3%, and 1%, respectively (P = 0.56). Conclusion: Patients with non-small cell lung cancer who have inoperable, nonmetastatic disease gain no clinically meaningful survival advantage with immediate thoracic irradiation, even when modern megavoltage radiation therapy techniques and equipment are used.Keywords
This publication has 17 references indexed in Scilit:
- Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology groupCancer, 1987
- Vinca alkaloids in the treatment of non-small cell lung cancerCancer Treatment Reviews, 1987
- Confidence Intervals for Reporting Results of Clinical TrialsAnnals of Internal Medicine, 1986
- Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1986
- Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinomaAmerican Journal of Clinical Oncology, 1984
- Vindesine: an Effective Phase II Agent in the Treatment of Non-Small Cell Lung CancerPublished by S. Karger AG ,1981
- A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the radiation therapy oncology groupCancer, 1980
- PHASE-II EVALUATION OF VINDESINE IN PATIENTS WITH NON-SMALL CELL-CARCINOMA OF THE LUNG1979
- SHOULD ASYMPTOMATIC PATIENTS WITH INOPERABLE BRONCHOGENIC CARCINOMA RECEIVE IMMEDIATE RADIOTHERAPY - NOPublished by Elsevier ,1978
- The role of radiotherapy in treatment of inoperable lung cancerInternational Journal of Radiation Oncology*Biology*Physics, 1977